Loading...

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient‐reported outcomes (PROs) in patients with RA treated with tofacitinib or placebo in combination with conventional disease‐modifying antirheumatic drugs (DMARDs). METHODS: In a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Arthritis Care Res (Hoboken)
Main Authors: Strand, Vibeke, Kremer, Joel M., Gruben, David, Krishnaswami, Sriram, Zwillich, Samuel H., Wallenstein, Gene V.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2017
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5413813/
https://ncbi.nlm.nih.gov/pubmed/27565000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23004
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!